Dr. Seiwert on Ongoing Trials in Head and Neck Cancer

Tanguy I. Seiwert, MD
Published Online: Monday, Feb 20, 2017



Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

Seiwert goes into detail with the phase I/II findings of the combination of lirilumab plus the PD-1 inhibitor nivolumab (Opdivo) in patients with squamous cell carcinoma of the head and neck (SCCHN), which led to an objective response rate (ORR) of 24.1%.

In the CheckMate-651 study, the CTLA-4 inhibitor ipilimumab (Yervoy) and nivolumab are being explored together, a combination that has demonstrated efficacy in other solid tumors. There are studies investigating immunotherapy and chemotherapy, as well, he adds.


Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

Seiwert goes into detail with the phase I/II findings of the combination of lirilumab plus the PD-1 inhibitor nivolumab (Opdivo) in patients with squamous cell carcinoma of the head and neck (SCCHN), which led to an objective response rate (ORR) of 24.1%.

In the CheckMate-651 study, the CTLA-4 inhibitor ipilimumab (Yervoy) and nivolumab are being explored together, a combination that has demonstrated efficacy in other solid tumors. There are studies investigating immunotherapy and chemotherapy, as well, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
$emailPop$